Introduction 28 29
Natural compounds of both plant and animal origin have traditionally been used in a 30 medicinal context due to their broad-spectrum of therapeutic activity, including; anti-bacterial, 31 fungal, and viral activity, as well as anti-inflammatory and immunomodulatory effects [1] [2] [3] [4] [5] [6] [7] [8] . In recent 32 years the interest in natural products as a potential source of novel antimicrobial agents has grown, 33 due to a concomitant decline in the number of effective antibiotics that are available and the ever 34 increasing emergence of antibiotic resistance within pathogenic bacteria [9] [10] [11] [12] [13] . This effect has been 35 compounded by a decline in the manufacture of new antimicrobial agents by traditional 36 pharmaceutical companies [14] [15] [16] , and both the over and misuse of the available antimicrobial agents 37 [17] [18] [19] . Together these factors have led to a situation whereby bacteria have evolved various 38 resistance mechanisms to conventional antibiotics and in some cases become multi drug resistant 39 (MDR) or pan resistant [20] [21] [22] [23] [24] [25] . 40
41
The rise of antimicrobial resistance (AMR) as outlined above is a significant global problem, 42 currently accounting for approximately 700,000 deaths annually, and predicted to lead to 10 million 43 deaths annually by 2050 if no action is taken to find alternative ways of combating MDR pathogens 44 16, 26 . In addition to the increased morbidity and mortality of patients caused by AMR there is also a 45 large financial burden causing an estimated cost of between $70,000 and $100,000 per person 27 . It 46 is likely that the cost of AMR is higher than the estimated figures, as there will also be an impact 47 on routine operations, such as joint replacements, which require prophylaxis in order to stop 48 secondary infections [27] [28] [29] . These factors combined illustrate the need for novel antimicrobial 49 agents, which can be used to bolster the lineup of currently available therapeutics as part of a 50 multidisciplinary strategy for reducing patient morbidity and mortality rates. 51
52
Within the wide range of natural products that are currently being investigated for their novel 53 antimicrobial activity, there has been a renewed interest in elucidating the antimicrobial activity of 54 apitherapeutics (bee products). There is a growing body of evidence that suggests bee products 55 such as honey, propolis, bee venom (BV) and honey bee defensins could have a role to play in 56 mitigating the effect of AMR, by providing an alternative source of antimicrobial activity, which 57 could be used to tackle infection alone or enhance the activity of current antimicrobial agents [30] [31] [32] [33] [34] [35] [36] [37] . 58
This review will consider a range of bee products and evaluate the evidence available for their 59 potential use as antimicrobial agents. 60
61
Antimicrobial properties of Honey. 62
63
For over two millennia, the medicinal properties of honey have been known to many historic 64 civilisations (such as the ancient Greeks, Romans, Egyptians, and Chinese), however much of this 65 knowledge was based on anecdotal evidence rather than designed scientific experimentation 38 . It 66 wasn't until late in the 19 th century when the first scientific publication showing the antimicrobial 67 efficacy of honey was published by Van Ketal 39 . Since this publication, bar a momentary pause at 68 the beginning of the antibiotic-era, interest in honey as an antimicrobial agent has increased. As stated 69 previously, this resurgence is in part due to the emergence of MDR pathogens 40 , but also due to the 70 natural qualities of honey and the breadth and depth of components from which it is composed. 71
72
Honey is a complex solution with three distinct "fractions"; a sugar fraction, water fraction, 73 and a highly variable fraction that contains a range of amino acids, antioxidants, enzymes, flavonoids, 74 phenolic acids, minerals, and vitamins. Both the sugar and water fractions are highly conserved 75 between different honey types 41 , conferring a basic level of antimicrobial activity through a high 76 osmotic potential and its acidic attenuation 42 . In many studies looking into the antimicrobial effects 77 of honey, an "artificial honey" formulated from these two fractions can be used as a control. In most 78 instances, the artificial honey is found to possess significantly reduced antimicrobial activity than that 79 of honey containing the variable fraction 43 . 80
81
The largest variation in honey composition, which alters the smell, taste, aroma, and ultimately 82 antimicrobial activity, occurs (unsurprisingly) within the variable fraction. This fraction is dependent 83 on both plant and bee-derived products, which in turn are subject to different environmental, 84 geographic, temporal, and phyletic variables 44, 45 . It is because of the highly variable nature of 85 summative components, that there are 100s of different honey types, each having varying degrees of 86 antibacterial efficacy, with some variability between batches of the same honey. A range of studies 87 (summarised in 46 ) have shown >50 bacterial species to be inhibited by these different honey types, 88 with some studies highlighting the anti-viral and anti-fungal properties of honey [47] [48] [49] [50] [51] . Determining 89 which of the compounds within the variable fraction contributes to the bulk antimicrobial activity of 90 each honey is very difficult, due to the potential for complex interactions between any of the 200 91 compounds that may be present within the honey 52 . 92
93
Some of the most promising compounds which are currently being researched are bee-defensin 94 1, hydrogen peroxide, leptosperin, and methylglyoxal 53, 54 . The former two can be found in many 95 different honeys and not associated with a specific type, whilst the latter two are commonly associated 96 specifically with manuka honey, a honey typically from New Zealand and Southern Australia, which 97 has received increased research interest due to its heightened antimicrobial activity. 71 . An 158 investigation of red Brazilian propolis, which is produced by bees foraging a red resin produced by 159 the Dalbergia ecastophyllum tree, also identified antimicrobial activity against S. aureus, although 160 this activity was variable and dependent on the season of collection 72 . In addition to the well-161 Royalisn, a defensin found exclusively within royal jelly, are very closely related and expressed by 213 the same gene within the bee, however they undergo different post-transcriptional and translational 214 modifications 91 . Defensin 2 is closely related, both genetically and structurally to defensin 1, 215 however it is expressed by a different gene 91 . Some of the antimicrobial activity of Revamil® 216 honey, a honey which is produced by bees foraging on limited plant sources in order to control its 217 content, is attributable to the presence of Defenisn 1 within the honey 54 . Neutralisation of defensin 218 1 leads to a reduction in the antimicrobial activity of the honey. It should be noted however, that the 219 inactivation of defensing-1 does not completely negate the antimicrobial activity of the honey, 220
highlighting the multifactorial nature of honey, as described above 54 . In contrast to these findings 221 in Revamil® honey, it has been shown that Defenisn 1 does not contribute to the antimicrobial 222 activity of manuka honey 94 . Recent work has shown that this is not due to differences in defensin 223 expression levels in the colonies foraging on the different plants, but rather the high levels of MGO 224 found within manuka honey 95 . MGO has an ability to react with lysine and arginine residues 225 within proteins, including defensin, leading to their glycosylation and subsequent inactivation 96 . 226 MGO levels in manuka honey have been shown to increase as the honey matures 97 and it is this 227 increase that leads to the inactivation of the defensin proteins which are secreted by the bees into 228 the original honey. 229 230
Antimicrobial properties of Royal Jelly 231 232
Royal jelly is a secretion produced in the hypopharingeal and mandibular glands of honey 233 bees 98 . As with many bee products, royal jelly is very variable in its composition, with its bioactive 234 potential affected by both seasonality and geographical diversity 99,100 . It is produced by worker 235 bees as a source of nutrition for larvae less than three days old and queen bees throughout their 236 lives, it contains complex combinations of pheromones which control the honey bee colony 237 The majority of the dry mass of royal jelly is protein, more than 80% of which are identified 265 as belonging to the major royal jelly proteins (MRJP) family, a member of which is MRJP1
109 . The 266 precursor of MRJP1 is also responsible for the production of the antimicrobial jellein peptides 110 . 267 Further structural analysis and comparison of the proteins expressed by different groups is required 297 to confirm this hypothesis. 298
Royal jelly also contains fatty acids, the most common of which is 10-hydroxy-2-decenoic 300 acid (10-HDA) 115 . As with other royal jelly components, 10-HDA has been shown to have a range 301 of bio-activities, including; antitumor activity 116 , neurogenesis 117 , anti-rheumatoid arthritis 302 activity 118 and modulation of diabetes 119 . 10-HDA also exhibits potent antimicrobial activity 303 against the Gram positive dental pathogen S. mutans. Furthermore, it was found that 10-HDA was 304 able to modulate biofilm formation within S. mutans by reducing expression of two 305 glucosyltransferases (gtfB and gtfC), which in turn led to a decrease in its attachment to embryonal 306 carcinoma cells 120 . 307
308

Antimicrobial properties of Bee Pollen 309 310
Bee pollen is composed of plant pollen combined with nectar or the salivary secretions of 311 bees. Therefore it is similar to other bee products in that it is composed of a wide range of 312 secondary plant metabolites such as: thiamine, tocopherol, biotin, niacin, folic acid, polyphenols, 313 carotenoid pigments, phytosterols and enzymes 121 There are several studies which report variability in the antimicrobial activity of bee pollen, 319 attributing this to the geographical and botanical source of the pollen, which in turn will influence 320 the phytochemical composition 121,129-133 . As a result of this variation, there are thought to be over 321 250 biologically active compounds within pollen [134] [135] [136] . The majority of work into the antibacterial 322 potential of pollen has been carried out on chemically extracted of pollen (using either ethanol ormethanol) and then tested in vitro. As with propolis extracts, the method by which the extracts are 324 made may well impact on the content and thus the activity of the extract that is then tested. 325
326
The antibacterial activity reported from bee pollen extracts is thought to be linked to the 327 presence of polyphenols (3-5%) and phenolic acids (0.19%) within the pollen, depending on origin identified the antimicrobial activity of BV to be pH-independent with comparable inhibitory efficacy 382 at a range of different pH levels (2-11). 383
384
The primary bee venom component (BVC), in terms of both dry weight (~50% w/w) and 385 biological activity, is the antimicrobial peptide; melittin 158 . This 26-amino acid residue has 386 exceptional non-selective lytic activity, capable of inhibiting both eukaryotic and prokaryotic cells 162 . 387
For a prospective antimicrobial agent this might appear to be counter intuitive, however the dose 388 required for bacteriolytic activity is much lower than that required to elicit a cytolytic effect for 389 eukaryotic cells 155, 163 . 390
391
The secondary BVC, in terms of both dry weight (~10% w/w) and more importantly biological 392 activity, is phospholipase A2. This hydrolase is capable of cleaving phospholipids and altering their 393 membrane association. There are significantly fewer studies on phospholipase A2 derived from BV 394 than its more common counterpart, however antimicrobial effects have been demonstrated against bothGram positive and negative bacteria 164 . Despite this, a recent study by Leandro and colleagues 165 
396
showed the inhibitory effects of phospholipase A2 to be less than melittin. In addition to this, the 397 combination of the two BVCs did not appear to interact effectively, concluding that the majority of 398 activity was due to the presence of melittin. This is in direct contrast to initial observations by Mollay 399 and collegues 166,167 whereby melittin was found to enhance the efficacy of phospholipase A2 400
Interestingly, a recent in vivo study showed melittin to be more effective than BV at reducing bacterial 401 load in a surface wound, whilst concurrently enhancing would healing 168 . 402 The additive and synergistic effects observed between BV/BVCs is interesting from a 414 therapeutic perspective. Due to the high cytotoxic effects associated with elevated doses of BV/BVCs, 415 reduced doses would be preferable. By combining the two, we may be able to reinvigorate ailing 416 antibiotics whilst also reducing potential side effects, both of which would be welcomed in clinical 417 practice. Importantly, whilst there is potential for BV and BVCs as antimicrobial agents, it is essential 418 that prospective patients are tested for potential allergies to apitherapy-products prior to treatment, so 419 as to avoid potential life-threatening side effects 420
421
Conclusion 422
The research presented within this review demonstrates that bee products including; honey, 423 propolis, honey bee peptides, royal jelly, bee pollen and bee venom show great promise as 424 antimicrobial agents against a wide range of microbial pathogens. All the bee products reviewed have 425 a broad spectrum of reported activity against both Gram positive and negative bacterial species and 426 several products also show promising activity against a range of fungal species of medical relevance. 427
One of the problems highlighted in this review is that many of the studies report varying levels of 428 antimicrobial activity due to the inherent variability, and poorly defined chemical nature of these 429 products. Many natural products show similar variances in composition and activity, however if 430 products are to be considered for use in modern medical applications they must have a consistent and 431 specific level of activity. This has already been achieved with products like medical grade manuka 432 honey and work is now beginning to classify propolis and its activity. It would be beneficial if other 433 apitherapeutics were to also undergo this process. Once antimicrobial activity, and the extraction 434 methods used to release the antimicrobial fractions are standardized and classified it will be possible 435 to make direct comparisons of products and their relative activity. Similarly, standardized and sterile 436 products are favoured for use in in vivo and in-patient studies, which is the natural next step for many 437 of the products reviewed here. 
